Halozyme Therapeutics HALO
NASDAQ HALO
$101.53 -0.15 (-0.15%)
As of: Nov 12, 2026 · 12:02 PM EST

Halozyme Therapeutics (HALO) Return on Sales [ROS] (2009 - 2026)

Updated

Halozyme Therapeutics (HALO) posted Return on Sales [ROS] of 59.80% for Q2 2026, down 2.35 percentage points from 62.15% a year earlier but up 10.82 percentage points from the prior quarter.

Analysis

Halozyme Therapeutics (HALO) Return on Sales [ROS] (2009 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Return on Sales [ROS] at Halozyme Therapeutics was 35.90%, down 22.02 percentage points year-over-year; for FY2025, it came in at 33.58%, down 20.73 percentage points from FY2024.

  • Annual Return on Sales [ROS] shows a five-year change of -20.33 percentage points (FY2020 to FY2025).
  • In prior years, Halozyme Therapeutics' Return on Sales [ROS] was 54.32% in FY2024 (+13.61 pp), 40.71% in FY2023 (+0.18 pp), 40.53% in FY2022 (-21.71 pp) and 62.24% in FY2021 (+8.33 pp).
  • Quarterly Return on Sales [ROS] has run from a low of -20.56% in Q4 2025 to a high of 65.26% in Q3 2021 over five years.
  • On a year-over-year basis, Return on Sales [ROS] has declined in each of the last three quarters, with an average year-over-year change of -4.31 percentage points over the last eight quarters.
  • The strongest year-over-year quarter for Return on Sales [ROS] in the past five years was Q2 2023, with a gain of 20.38 percentage points; the weakest was Q4 2025, with a drop of 79.45 percentage points.
  • According to Business Quant data, Return on Sales [ROS] for the three prior quarters was 48.98% (Q1 2026), -20.56% (Q4 2025) and 61.51% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Halozyme Therapeutics 11.73 Bn 9.97 Bn 410.50 Mn 59.83%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 59.83%
Jun 30, 2026 59.80%
Mar 31, 2026 48.98%
Dec 31, 2025 -20.56%
Sep 30, 2025 61.51%
Jun 30, 2025 62.15%
Mar 31, 2025 53.44%
Dec 31, 2024 58.89%
Sep 30, 2024 56.26%
Jun 30, 2024 50.67%
Mar 31, 2024 48.78%
Dec 31, 2023 43.92%
Sep 30, 2023 40.86%
Jun 30, 2023 42.73%
Mar 31, 2023 33.18%
Dec 31, 2022 41.05%
Sep 30, 2022 39.86%
Jun 30, 2022 22.35%
Mar 31, 2022 64.52%
Dec 31, 2021 55.42%
API Access

Halozyme Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=HALO&period=max&api_key=YOUR_API_KEY